首页> 美国卫生研究院文献>Journal of Clinical Medicine >Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use
【2h】

Categorization of Marketed Artificial Tear Formulations Based on Their Ingredients: A Rational Approach for Their Use

机译:基于其成分的营销人工撕裂配方分类:其使用的合理方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dry eye disease is a common ocular condition affecting millions of people worldwide. Artificial tears are the first line therapy for the management of dry eye disease. Artificial tear formulations contain a variety of active ingredients, biologically active excipients, and preservatives. Many of these formulations are also available as preservative-free. This study was conducted to inspect artificial tear formulations currently marketed in the United States for their active ingredients, biologically relevant excipients, and preservatives. The marketed artificial tears were examined at various US retail pharmacy chains and using the manufacturers’ website to compile information about active ingredients, inactive ingredients, and preservatives. The currently marketed artificial tears can be grouped into four categories based on their active ingredients. The artificial tears also contain biologically active chemicals listed as inactive ingredients, which have osmoprotectant, humectant, and tear film lipid layer or mucous layer mimicking properties. Most artificial tears contain vanishing type preservatives such as purite or sodium perborate and safer quaternary compound polyquaternium-1. The majority of these artificial tear formulations are also available as preservative-free single dose unit. The study provides a formulary of artificial tears based on active ingredients, biologically active excipients, and the preservative-free option. The formulary should assist healthcare providers in making a stepwise and rational selection of appropriate artificial tears for patients suffering from dry eye disease.
机译:干眼症是一种影响全球数百万人的常见眼部条件。人造泪是一种用于治疗干眼症的第一线疗法。人工泪液配方含有各种活性成分,生物活性赋形剂和防腐剂。其中许多配方也可用作防腐剂。本研究进行了在美国销售的人工泪液配方,以获得活性成分,生物相关赋形剂和防腐剂。在美国零售药房链中检查了市场的人造泪,并使用制造商网站编制有关有源成分,非活性成分和防腐剂的信息。目前销售的人工泪液可以根据活性成分分为四类。人工泪液还含有作为非活性成分的生物活性化学品,其具有渗透剂,保湿剂和泪膜脂层或粘膜层模仿性能。大多数人工泪液含有消失的防腐剂,如乳磷酸盐或哌氢钠,更安全的季化合物多样性核-1。这些人工撕裂配方的大部分也可用作无防腐剂单剂量单位。该研究提供了基于活性成分,生物活性赋形剂和无防腐剂选择的人造泪泪的形式。该形式化应帮助医疗保健提供商在患有干眼症患者的患者的逐步和理性选择适当的人造泪液。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号